Meet us at…
Latest news
Exploring the Antifibrotic Potential of the heparan sulfate mimetic OTR4120: Insights from Preclinical Models Manuela Marega1,2,3, Najet Mejdoubi-Charef4 , David Wiegard1, Muzamil Majid Khan5,6, Marek Bartkuhn2, Laura Gambs2, Tara Procida-Kowalski2, Jochem Wilhelm2, Esmeralda Vasquez-Pacheco1, Afshin Noori1,2, Ying Dong1,2, Yi Zheng7, Xuran Chu7, Arun Lingampally1,2, Joanna Zukowska5,6, Said Charef8,9, Franck Chiappini8,9, [...]
7 October 2025
Next-Generation Biomaterials for Wound Healing: Development and Evaluation of Collagen Scaffolds Functionalized with a Heparan Sulfate Mimic and Fibroblast Growth Factor 2 Merel Gansevoort 1 , Sabine Wentholt 1, Gaia Li Vecchi 1, Marjolein de Vries 1, Elly M. M. Versteeg 1, Bouke K. H. L. Boekema 2,3 , Agnes [...]
7 October 2025
Intra‑arterial Injection of OTR4132, a Novel Neuroprotector in Acute Ischemic Stroke: The MaTRISS Trial Xavier Barreau1 · René Anxionnat2 · Olivier Heck3 · Igor Sibon4,5 · Charlotte Rosso6 · Catherine Oppenheim7 · Francisco Moniche8 · Frédéric Sedel9 · Franck Chiappini9 · Agnès Choppin9 · Martin Inizan9 · Denis Barritault9 · [...]
6 October 2025
Lecture from Aubert de Lichy Structure resolution of glucose units in a heparan sulfate mimetic (RGTA®) fragment by NMR and molecular dynamics simulations Abstract: ReGeneraTing Agents (RGTA®) are synthetic polysaccharides designed to mimic the structural and functional properties of heparan sulfates (HS), essential components of the extracellular matrix that are [...]
30 May 2025
OPTIMIZATION OF EXTRACELLULAR VESICLES-BASED THERAPY IN THE TREATMENT OF ISCHEMIC STROKE Poster Session on the Friday 25th of April at 4:30PM at ISEV Congress in Vienna Ons BEN HADJ HASSEN1, Sarah RAZAFINDRAKOTO2, Jérôme TOUTAIN1, Isis BLANCHARD1, Viktoriia IVANOVA1, Charlène RENOULT1,3, Xavier LAFFRAY4, Minh-Bao HUYNH4, Carole BRUNAUD1, Karim BORDJI1, Gael LE [...]
10 April 2025
OTR3 has initiated its Phase 2 clinical trial for OTR4132, a novel neuroprotector designed to enhance functional recovery in acute ischemic stroke patients following thrombectomy. A first-in-human pilot study, MATRISS, was conducted across three centers in France, evaluating six escalating doses. The results were promising, demonstrating favorable safety and efficacy [...]
18 March 2025
Overview of 10 years of practice with CACIPLIQ20® matrix therapy as a healing agent for hard to heal wounds: Efficacy, cost-effectiveness and future perspectives Background: Chronic, non-healing wounds remain a major challenge for health care practitioners and for society in general, both in terms of the enormous economic burden [...]
18 March 2025
Merel Gansevoort 1 , SabineWentholt 1, Gaia Li Vecchi 1, Marjolein de Vries 1, Elly M. M. Versteeg 1, Bouke K. H. L. Boekema 2,3 , Agnes Choppin 4, Denis Barritault 4, Franck Chiappini 4 , Toin H. van Kuppevelt 1 and Willeke F. Daamen 1,* Fibrosis after full-thickness wound [...]
11 February 2025
